The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

Dave Coulier recently revealed another cancer diagnosis, mere months after recovering from Stage 3 non-Hodgkin’s lymphoma ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Dave Coulier has been diagnosed with HPV-related tongue cancer, just months after going into remission from stage 3 ...

Dave Coulier has revealed that he is undergoing treatment for tongue cancer, just a year after he beat non-Hodgkin lymphoma.

Citius Oncology launches US FDA approved Lymphir, a novel cancer immunotherapy for cutaneous T-cell lymphoma: Cranford, New Jersey Wednesday, December 3, 2025, 16:00 Hrs [IST] Cit ...

“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for ...

Earlier this week, Bristol Myers Squibb announced that the European Commission approved its CAR-T cell therapy Breyanzi for ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

Dave Coulier announced he is undergoing treatment for tongue cancer nearly eight months after he beat his battle with ...

Citius Pharmaceuticals ( ($CTXR) ) has issued an update. On December 1, 2025, Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, ...

Coulier, 66, was diagnosed with HPV-related oropharyngeal tongue cancer in October, he told TODAY.com in a phone interview.